There is no clear evidence of an increased risk for myocardial infarction, stroke, or other cardiovascular events associated with the use of entacapone for the treatment of Parkinson's disease (PD), a ...

Alembic has received the Food and Drug Administration’s permission for entacapone tablets in a dosage strength of 200 mg. The product is the generic of Orion’s Comtan. The drug is indicated as an ...

Sun Pharmaceutical Industries Ltd announced that together with its affiliates (?Sun Pharma?) it has executed a settlement agreement with Orion stipulating a dismissal of the lawsuits filed in the ...

CHICAGO (Reuters) - Drugs used to treat Parkinson's disease show promise as a new way to stem the rise of drug-resistant forms of tuberculosis, U.S. researchers said on Thursday. They said computer ...

Mylan Inc. said Thursday that it had reached an agreement to settle patent litigation over the generic version of Orion Corp.'s Comtan. Mylan Inc. said Thursday that it had reached an agreement to ...

[03-31-2010] The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data that may suggest that patients taking Stalevo, a Parkinson's disease medication, may be at an increased risk ...

Company states the realisation of generic competition is still neither certain nor imminent Orion Corporation has been informed that Sun Pharma Global, Inc. has filed an Abbreviated New Drug ...

Wockhardt has got USFDA nod for generic version of Comtan, reports CNBC-TV18. The share touched a 52-week high of Rs 1,325. At 09:24 hrs the share was quoting at Rs 1,318.00, up Rs 19.35, or 1.49%.

HELSINKI, Nov 12 (Reuters) - Finnish drug firm Orion said on Wednesday it has filed a patent infringement lawsuit in the United States to protect its key drug Comtan, used for treatment of Parkinson's ...